

Final - August 30, 2021

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

August 30, 2021

	<u>AGENDA ITEM</u>	<u>PRESIDER/PRESENTER(S)</u>
Monday, August 30, 2021		
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
10:15	Coronavirus Disease 2019 (COVID-19) Vaccines Introduction BNT-162b2 COVID-19 vaccine BLA safety and efficacy data	Dr. Matthew Daley (ACIP, WG Chair) Dr. John Perez (Pfizer-BioNTech)
11:00	Break	
11:15	Public Comment	
11:45	Break	
12:00	Safety update for COVID-19 vaccines: VAERS Safety update for COVID-19 vaccines: VSD VaST assessment Benefit-risk discussion for use of Pfizer-BioNTech COVID-19 vaccine in individuals ≥16 years of age	Dr. John Su (CDC/NCEZID) Dr. Nicola Klein (Kaiser Permanente Northern California) Dr. Grace Lee (ACIP, VaST Co-chair) Dr. Hannah Rosenblum (CDC/NCIRD)
1:30	Break	
1:45	GRADE: Pfizer/BioNTech COVID-19 vaccine Evidence to Recommendations Framework: Pfizer-BioNTech COVID-19 vaccine	Dr. Julia Gargano (CDC/NCIRD) Dr. Kathleen Dooling (CDC/NCIRD)
2:45	Break	
3:00	Discussion VOTE Pfizer/BioNTech COVID-19 vaccine for individuals ≥16 years of age	Dr. Kathleen Dooling (CDC/NCIRD)
3:30	Break	
3:45	Framework for COVID-19 booster doses Discussion	Dr. Sara Oliver (CDC/NCIRD)
4:30	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness